Ensayo clínico

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

NCT: NCT05977036 · RECRUITING

ID NCTNCT05977036

EstadoRECRUITING

Fecha de inicio2024-09-25

Finalización2035-09-30

SponsorWashington University School of Medicine (OTHER)

First posted2023-08-04

Last updated2026-10-09

Resumen breve

This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with hormone receptor (HR) positive, HER-2 negative metastatic or unresectable breast cancer receiving first-line or second-line treatment.

Fuente oficial

Ver en ClinicalTrials.gov →

Datos obtenidos de la API de ClinicalTrials.gov. Para conocer el estado más reciente, consulte el registro oficial.